{"id":"NCT01296360","sponsor":"Valneva Austria GmbH","briefTitle":"Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country","officialTitle":"Long-Term Immunity and Safety With or Without a Booster Dose Following Primary Vaccination With the Japanese Encephalitis Vaccine IC51 (IXIAROÂ®) in a Pediatric Population in a JEV-Endemic Country. Open-Label, Randomized, Phase 3 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2011-11","completion":"2013-10","firstPosted":"2011-02-15","resultsPosted":"2014-12-19","lastUpdate":"2014-12-19"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IXIARO","otherNames":[]},{"type":"BIOLOGICAL","name":"IXIARO","otherNames":[]}],"arms":[{"label":">14 months to <2 years","type":"ACTIVE_COMPARATOR"},{"label":">3 years - <18 years","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, open-label Phase 3 study including children aged \\>9 months to \\<17 years and 7 months who have been vaccinated with IXIARO in study IC51-323.","primaryOutcome":{"measure":"SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of>1:10 at 1 Month After the Booster Dose","timeFrame":"1 month post booster","effectByArm":[{"arm":">14 Months to <2 Years","deltaMin":100,"sd":null},{"arm":">3 Years - <18 Years","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":3,"countries":["Philippines"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":150},"commonTop":["Upper respiratory tract infection","Rhinitis","Nasopharyngitis","Varicella","Pyrexia"]}}